Alexion Pharmaceuticals Inc drugs
7 results
Hlal rdna construct in sbc lal-c chickens (hlal rdna construct in sbc lal-c chicken)
(HLAL RDNA CONSTRUCT IN SBC LAL-C CHICKEN)Alexion Pharmaceuticals Inc
Inpefa (sotagliflozin)
(sotagliflozin)Alexion Pharmaceuticals Inc
Usage: INPEFA is indicated for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
Kanuma (sebelipase alfa)
(Sebelipase alfa)Alexion Pharmaceuticals Inc
Usage: KANUMA® is indicated for the treatment of patients diagnosed with Lysosomal Acid Lipase (LAL) deficiency.
Soliris (eculizumab)
(ECULIZUMAB)Alexion Pharmaceuticals Inc
Usage: SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit thrombotic microangiopathy, generalized myasthenia gravis (gMG) in patients aged six and older, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 positive adults.
Strensiq (asfotase alfa)
(ASFOTASE ALFA)Alexion Pharmaceuticals Inc
Usage: STRENSIQ® is indicated for the treatment of patients with perinatal/infantile and juvenile-onset hypophosphatasia (HPP).
Ultomiris (ravulizumab)
(ravulizumab)Alexion Pharmaceuticals Inc
Usage: ULTOMIRIS is indicated for treating adult and pediatric patients aged one month and older with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Additionally, it is used for adult patients with generalized myasthenia gravis (anti-AChR antibody-positive) and neuromyelitis optica spectrum disorder (AQP4 antibody-positive).
Voydeya (danicopan)
(Danicopan)Alexion Pharmaceuticals Inc
Usage: VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for treating extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. It is not effective as a monotherapy and should only be used alongside these medications.